Skip to main content

Stage IV or Recurrent Non-Small Cell Lung Cancer with +AGA (Lung-MAP Sub-Study S1900N)

Status: Open to Enrollment
Email Us To Enroll

Study Details

View study details on clinicaltrials.gov.

Locations

  • Sutter Health System Wide

Clinical Trial FAQs

Information for patients and study volunteers, including frequently asked questions.

A Randomized Phase II Study of Sacituzumab Govitecan Alone, Ivonescimab Alone, or Sacituzumab Govitecan and Ivonescimab in Participants With Previously-Treated Actionable Genomic Alteration Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

Ari D Baron, M.D.
Ari D Baron, M.D.
Principal investigator
View Profile

You're leaving our site

The website you have selected is an external one located on another server. This website may contain links to third party sites. These links are provided for convenience purposes and are not under the control of Sutter Health. Do you wish to continue?